Turning voice into a new layer of respiratory intelligence
We build voice-based biomarkers through acoustic analysis of voice and breath, enabling scalable detection and monitoring of respiratory health
Turning voice into a new layer of respiratory intelligence
We build voice-based biomarkers through acoustic analysis of voice and breath, enabling scalable detection and monitoring of respiratory health
Why we exist
Vision
Everyone, everywhere
is empowered to achieve
their best health
Mission
Simplifying healthcare access
with convenient & reliable
vocal biomarkers
Impact
Improve patients’ quality of life, reduce healthcare costs and
make a happier society
“Have you ever wondered what a future without illness could look like? Imagine being able to catch health issues before they become serious. You wake up, say, “Good morning, VoiceMed” and instantly receive guidance on whether you need to see a doctor or not, before you even realize something might be wrong. We foster proactive healthcare, focusing on early detection and preventing disease progression.”
Arianna Arienzo
CEO VoiceMed Italia Srl
We don’t build prototypes.
We build solutions designed to operate at scale
VoiceMed was born at the intersection of science, personal drive and a global health crisis.
In 2020, during the COVID-19 pandemic, Arianna, motivated by her business background and personal context, living in a family of pulmonologist doctors, set out to make healthcare more accessible.
In 2021, she teamed up with Fulvio Cordella, who was working on vocal biomarkers, passionate about voice from a scientific and artistic point of view (being both a biomedical engineer and a voice actor). They decided to solve the unmet need in respiratory health with vocal biomarkers.
The team came full circle in 2024 with the arrival of Martina, a medical doctor in preventive medicine, who strengthened the medical vision. Martina dedicated the last 10 years of her work to support respiratory health through smoking cessation. Together, they are building VoiceMed to bring proactive and accessible healthcare to everyone, everywhere, starting with European adults over 50 smokers.
Leadership
Arianna Arienzo
Chief Executive Officer
- Msc in business adm. & Fulbright program in entrepreneurship
- 4+ years of experience as entrepreneur in digital health
- Contract professor of healthcare innovation at Cattolica University
Fulvio Cordella
Chief Technology Officer
- MSc in biomedical engineering
- 3+ years of experience as vocal biomarkers engineer
- Previous experience in Technoscience as vocal biomarkers researcher
Fulvio has a deep and unique understanding of sound, which he’s explored both artistically and scientifically. As a musician and voice actor with a degree from the dubbing academy, he delved into it from an artistic point of view. As a biomedical engineer, he discovered the scientific applications of sound in e-health. His journey began at Technoscience, where he was a vocal biomarkers researcher. Now, at VoiceMed, Fulvio develops advanced combinations of algorithms and manages the AI team to continually improve the performance of our vocal biomarkers, creating disruptive innovation in digital health.
Dr. Martina Antinozzi
Medical manager
- Medical doctor specialised in public health
- 5+ years of experience in hospitals
- 7+ years of experience in medical societies
A multidisciplinary team, with a strong network
We combine AI, clinical, and product expertise to build and deploy solutions in real-world healthcare settings
Luca Panzarella
Product manager
A 15+ years experienced product manager, UX and product designer.
He worked in the tech ecosystem in San Francisco, Rome, London and Milan. He used to run his own tech company before joining VoiceMed.
Daniele Mascali
Senior Artificial Intelligence engineer
A physicist with a PhD in biophysics.
He worked 9+ years as a researcher in computer science, deep learning etc. Previous experience in the field of magnetic resonance imaging applied to the study of brain function and its pathological alterations.
Silvia Losardo
Clinical Affairs Manager
A biologist with experience in getting approved by 2 ethical committees, managing 5 clinical studies, and recruiting +1900 patients. She works to maximise data quantity and quality, adhering to GCP practices and regulatory requirements.
Francesco Saverio Quatrano
Cybersecurity engineer
A 10+ years of experience engineer with skills in IT risk management, data protection, security governance process and regulations. Expertise in grant writing for European grants as well as national grants.
Advisors
Matteo Bonini
University Professor and pneumologist at Policlinico Umberto I
- Honorary Clinical Senior Lecturer at the Imperial College London
- Member of the GINA Science Committee and the ERS College of Experts
- Author of >150 scientific publications reviewed by JCR, with >10,000 citations and an H-index of 55 (Scholar)
Enrico Heffler
Director of the Postgraduate Residency Program for Allergology and Immunology
- Allergist and Clinical Immunologist, Assistant at Personalized Medicine, Asthma and Allergy Unit, Humanitas Research Hospital
- Author of more than 200 scientific articles published in international peer-reviewed scientific journals.
Francesca Puggioni
Head of Section Responsible for ImmunoCenter Humanitas
- Head of Section Responsible for ImmunoCenter Humanitas.
- Adjutant Teaching Professor in Respiratory Diseases at the Department of Internal Medicine and Therapeutic, Humanitas University Milan.
Loreta Di Michele
Director of the Pulmonary and Interstitial Lung Disease Unit at the San Camillo Forlanini Hospital
- Expert in the clinical management of complex respiratory pathologies
- Pioneer in personalized therapy and multidisciplinary care models for severe asthma, COPD, and rare lung diseases
- Scientific Director of ItaliaSonno, leading national research of sleep medicine
Giovanni Paoletti
Allergist and Clinical Immunologist
- Internal Medicine Researcher at Humanitas University
- Regional President of SIAAIC Lombardy Section
- Member of the Methodology Committee EAACI
Our journey
From research to real-world deployment, we went across business need validation, deep-tech development, clinical validation and market entry
Clinical need validation and initial data collection trough clinical studies
In 2021, the clinical need was defined and concept formulated. It was performed stakeholder mapping across multiple EU countries, benchmarking of existing respiratory technologies, and identification of the scientific hypothesis that vocal biomarkers can reflect lung health.
In 2022, initial audio pipeline was achieved through initial ethics-approved pilot studies in Italy and Luxembourg. Early web-based prototypes were tested on patients to collect recordings, building the initial version of quality checks.
Proof of concepts in hospital environment and usability testing at home
In 2023, VoiceMed developed initial technical Proof-Of-Concepts with patients data obtained in a controlled hospital environment at Humanitas Research Hospital. Patients underwent induced respiratory variations, enabling the collection of synchronized audio recordings and spirometry data across six distinct stages. The results showed a strong alignment between acoustic biomarkers and pulmonary function trends, reaching up to 99% correlation. Peer review publication available.
In parallel, the Airlyn mobile application was launched to test the usability in real world settings. The introduction of real-time quality control algorithms significantly improved execution reliability, with up to 92% of users correctly completing the test.
Starting clinical validation studies and paid pilot with digital health provider
In 2024, VoiceMed reached a major milestone by combining clinical validation with real-world deployment.
We expanded our collaboration with two hospitals to start new clinical studies for validating the technology on a large population (with Humanitas Research Hospitals and San Camillo Forlanini Hospital).
At the same time, we signed a paid pilot with YouHealthy, by integrating our technology though our Software Development Kit (SDK) into Youhealthy app, enabling their users to access wellness vocal biomarkers.
Clinical validation with 1’900 patients, pilot with industry partner and 1M€ round
In 2025, VoiceMed completed the clinical validation studies enrolling 1’900 patients that were split within training, test and validation.
In parallel, VoiceMed started a paid pilot with Chiesi, a global pharmaceutical company focused on respiratory health acting as industry partner, to showcase the impact on case finding and screening.
At the end of the year, VoiceMed completed its first investment round in equity, welcoming 3 investors onboard.
From real-world prospective studies, to CE mark certification, to market entry
In 2026, VoiceMed started new prospective studies to show the usage of the technology in the real world. Within 2026 -2027, we aim to achieve:
- Prospective pre market clinical studies, showing the solution in a real clinical workflow,
- Get the CE mark certification as medical device software class IIA,
- Enter the market, starting with the prospects who have signed Letter Of Intent (LOI) and moving forward to scale Europe and behind.